CRP and non-small cell lung carcinoma: These hypotheses are supported by recent studies highlighting CRP as the most prognostic clinicopathological marker for survival in non-small cell lung cancer (n=751) (12) and urothelial cancer (n=896) (13) cohorts treated with the ICI atezolizumab.